Health and Healthcare
Are More Positive Results on the Way for Kamada's COVID-19 Pneumonia Treatment?
Published:
Kamada Ltd. (NASDAQ: KMDA) took a big step in the fight against COVID-19 on Tuesday when the biopharmaceutical company announced initial interim results from its ongoing midstage coronavirus study of its treatment of COVID-19 patients with pneumonia.
Specifically, the results come from the ongoing Phase 1/2 clinical trial in Israel of the company’s anti-SARS-CoV-2 plasma-derived hyperimmune immunoglobulin (IgG) product as a potential treatment for COVID-19.
A total of 12 eligible patients (age 34 to 69) were enrolled in the trial and received the company’s product at a single dose of 4g IgG within five to 10 days of initial symptoms. Patient follow-up will occur for 84 days.
So far, five of the 12 patients have completed 21-day post-treatment follow-up, two patients have completed 14-day post-treatment follow-up and the additional five patients have completed seven-day post-treatment follow-up.
Symptoms improvement was observed in 11 of the 12 patients within 24 to 48 hours from treatment. All 11 patients were subsequently discharged from the hospital within a median hospital stay of 4.5 days from treatment.
Management expects that the final trial results will be available by January 2021 and that they will support the clinical plan to advance its IgG product as a potential treatment for hospitalized COVID-19 patients.
The U.S. Food and Drug Administration (FDA) recently issued an Emergency Use Authorization for convalescent plasma as a potential treatment for COVID–19. The plasma-derived IgG product, as developed by Kamada, is considered to have multiple advantages over convalescent plasma transfusion, such as standardized antibody levels, higher potency, extensive viral inactivation processing, the absence of a blood-type matching requirement, smaller infusion volumes and the ability to be produced in large quantities.
Kamada stock traded up about 8% to $9.45 on Tuesday, in a 52-week range of $4.40 to $13.33. The consensus price target is $11.00.
The Average American Is Losing Their Savings Every Day (Sponsor)
If you’re like many Americans and keep your money ‘safe’ in a checking or savings account, think again. The average yield on a savings account is a paltry .4% today, and inflation is much higher. Checking accounts are even worse.
Every day you don’t move to a high-yield savings account that beats inflation, you lose more and more value.
But there is good news. To win qualified customers, some accounts are paying 9-10x this national average. That’s an incredible way to keep your money safe, and get paid at the same time. Our top pick for high yield savings accounts includes other one time cash bonuses, and is FDIC insured.
Click here to see how much more you could be earning on your savings today. It takes just a few minutes and your money could be working for you.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
